Research programme: protein folding modulators - Reata Pharmaceuticals

Drug Profile

Research programme: protein folding modulators - Reata Pharmaceuticals

Alternative Names: Protein folding modulators - Reata Pharmaceuticals; Protein misfolding reagents for neurodegenerative diseases - Reata Pharmaceuticals; RTA 801; SOD1 reactivators - Reata Pharmaceuticals; SOD1 stabilisers - Reata Pharmaceuticals

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Reata Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Protein folding modulators; Superoxide dismutase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease; Parkinson's disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Alzheimer's-disease in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for research development in Huntington's-disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top